

News Releases

All Years



Search

GO

[Advanced Search](#)

Aug 9, 2018

Portola Pharmaceuticals Appoints Ernie Meyer as Executive Vice President and Chief Human Resources Officer

SOUTH SAN FRANCISCO, Calif., Aug. 09, 2018 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq:PTLA) today announced the appointment of Ernie Meyer as executive vice president and chief...

Aug 9, 2018

Portola Pharmaceuticals Reports Second Quarter 2018 Financial Results and Provides Corporate Update

- Conference Call Today at 8:30 a.m. ET -

SOUTH SAN FRANCISCO, Calif., Aug. 09, 2018 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq:PTLA) today reported financial results for the three months ended June 30, 2018 and provided...

Aug 3, 2018

U.S. Centers for Medicare and Medicaid Services (CMS) Grants New Technology Add-On Payment for Portola Pharmaceuticals' Andexxa

- Add-on payment to support patient access by providing additional Medicare reimbursement in the hospital setting -

SOUTH SAN FRANCISCO, Calif., Aug. 03, 2018 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq:PTLA) today announced that the U.S. Centers for Medicare and Medicaid Services (CMS) has...

Aug 2, 2018

Portola Pharmaceuticals to Announce Second Quarter 2018 Financial Results and Host Conference Call on Thursday, August 9, 2018

SOUTH SAN FRANCISCO, Calif., Aug. 02, 2018 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (NASDAQ:PTLA) today announced that it will host a webcast and conference call to discuss the...

Jul 27, 2018

European CHMP Maintains Negative Opinion on Portola Pharmaceuticals' Betrixaban Following Appeal

SOUTH SAN FRANCISCO, Calif., July 27, 2018 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq:PTLA) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the...

Jul 3, 2018

Portola Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif., July 03, 2018 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (NASDAQ:PTLA) announced today that on June 27, 2018, the Compensation Committee of the Board of...

Jun 25, 2018

Portola Pharmaceuticals Appoints 30-Year Industry Veteran Glenn Brame as Senior Vice President of Technical Operations

SOUTH SAN FRANCISCO, Calif., June 25, 2018 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.®

SOUTH SAN FRANCISCO, Calif., June 25, 2018 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq:PTLA) today announced the appointment of Glenn Brame as senior vice president of technical...

Jun 5, 2018

Portola Pharmaceuticals to Present at Two Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., June 05, 2018 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq:PTLA) today announced that the company will present at the following conferences in June:...

Jun 4, 2018

New Interim Phase 2a Study Results Demonstrate Broad Clinical Activity of Portola Pharmaceuticals' Oral SYK/JAK Inhibitor Cerdulatinib

- Differentiated SYK-JAK Inhibitor Shows Efficacy in Patients with Heavily Pre-Treated B- and T-Cell Malignancies -

SOUTH SAN FRANCISCO, Calif., June 04, 2018 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq:PTLA) today announced new interim results from the Company's ongoing Phase 2a study of...

Jun 4, 2018

Portola Pharmaceuticals Announces Retirement of CEO Bill Lis in 2018

SOUTH SAN FRANCISCO, Calif., June 04, 2018 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq:PTLA) today announced that William Lis has informed the Board of Directors of his plans to...

May 24, 2018

Portola Pharmaceuticals Receives \$100 Million Milestone Payment from HealthCare Royalty Partners for FDA Approval of Andexxa®


SOUTH SAN FRANCISCO, Calif., May 24, 2018 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq:PTLA) today announced that the company has received a \$100 million milestone payment from...

May 9, 2018

Portola Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Corporate Update

-- Conference Call Today at 4:30 p.m. ET --

SOUTH SAN FRANCISCO, Calif., May 09, 2018 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq:PTLA) today reported financial results for the three months ended March 31, 2018 and provided...



May 3, 2018

U.S. FDA Approves Portola Pharmaceuticals' Andexxa®, First and Only Antidote for the Reversal of Factor Xa Inhibitors

- Breakthrough Product is a Major Advance in the Treatment of Patients Hospitalized with Life-Threatening Bleeding -

SOUTH SAN FRANCISCO, Calif., May 03, 2018 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq:PTLA) today announced that the U.S. Food and Drug Administration (FDA) has approved Andexxa®...

 [Photos \(2\)](#)

Apr 30, 2018

Portola Pharmaceuticals to Announce First Quarter 2018 Financial Results and Host Conference Call on Wednesday, May 9, 2018

SOUTH SAN FRANCISCO, Calif., April 30, 2018 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (NASDAQ:PTLA) announced today that it will host a webcast and conference call to discuss the...

Apr 25, 2018

Portola Pharmaceuticals to Present New Interim Phase 2 Data for Cerdulatinib at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting

- Novel Oral SYK/JAK Inhibitor for Relapsed/Refractory B-cell and T-cell Cancers -

SOUTH SAN FRANCISCO, Calif., April 25, 2018 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq:PTLA) today announced that new interim results from the Company's ongoing Phase 2a study...

Apr 4, 2018

Portola Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif., April 04, 2018 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (NASDAQ:PTLA) announced today that on March 29, 2018, the Compensation Committee of the Board of...

Mar 23, 2018

Portola Pharmaceuticals Receives and Plans to Appeal Negative CHMP Opinion Regarding Marketing Authorization for Betrixaban in the European Union

SOUTH SAN FRANCISCO, Calif., March 23, 2018 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq:PTLA) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the...

Mar 12, 2018

Portola Pharmaceuticals Appoints Biotech Legal Veteran John Moriarty as Executive Vice President and General Counsel

SOUTH SAN FRANCISCO, Calif., March 12, 2018 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq:PTLA) today announced the appointment of John B. Moriarty, J.D., as executive vice president...

Mar 12, 2018

Portola Pharmaceuticals Announces New Interim Results from Ongoing ANNEXA-4 Study of Factor Xa Inhibitor Reversal Agent AndexXa® (Andexanet Alfa) in Patients with Life-Threatening Bleeding

- Excellent or Good Hemostasis Achieved in 83 Percent of Patients; Thrombotic Events Consistent with High Background Thrombotic Risk -

SOUTH SAN FRANCISCO, Calif., March 12, 2018 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq:PTLA) today announced new interim results from ANNEXA-4, the Company's ongoing Phase 3b/4...

Mar 6, 2018

Portola Pharmaceuticals to Present at Two Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., March 06, 2018 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (NASDAQ:PTLA) today announced that Bill Lis, chief executive officer, will present at the following...

Mar 5, 2018

Portola Pharmaceuticals to Host Webcast Event and Conference Call at ACC.18 to Discuss Late-Breaking Oral Presentation Highlighting New Interim Data for Andexanet Alfa

Event Scheduled for Monday, March 12, 2018 at 12:30 p.m. ET

SOUTH SAN FRANCISCO, Calif., March 05, 2018 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (NASDAQ:PTLA) today announced that it will host a live audio webcast and conference call on Monday...

Feb 28, 2018

Portola Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Corporate Update

--Conference Call Today at 4:30 p.m. ET--

SOUTH SAN FRANCISCO, Calif., Feb. 28, 2018 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (NASDAQ:PTLA) today reported financial results for the fourth quarter and full year ended December...

Feb 20, 2018

Portola Pharmaceuticals Announces Results of CHMP Oral Explanations for Andexanet Alfa and Betrixaban

Company to Host Conference Call on Tuesday, February 20, 2018, at 5:00 p.m. ET

SOUTH SAN FRANCISCO, Calif., Feb. 20, 2018 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq:PTLA) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the...

Feb 15, 2018

Portola Pharmaceuticals to Announce Fourth Quarter and Full Year 2017 Financial Results and Host Conference Call on Wednesday, February 28, 2018

SOUTH SAN FRANCISCO, Calif., Feb. 15, 2018 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (NASDAQ:PTLA) today announced that it will host a webcast and conference call to discuss the...

Jan 22, 2018

Portola Pharmaceuticals Announces Acceptance of Late-Breaker Abstract Highlighting New Data for Andexanet Alfa at ACC.18

SOUTH SAN FRANCISCO, Calif., Jan. 22, 2018 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq:PTLA) today announced that an abstract detailing interim results from the Company's ongoing...

Show 25  per page

 [1](#) [2](#) [3](#) [4](#) [5](#) [6](#) [7](#) [8](#) [9](#) [10](#) 



<https://investors.portola.com/news-releases?!=25&o=50>